Talk:Pentamidine

From WikiProjectMed
Jump to navigation Jump to search

Wiki Education Foundation-supported course assignment

This article is or was the subject of a Wiki Education Foundation-supported course assignment. Further details are available on the course page. Student editor(s): Jcua28, Mlmtabs, NedaNassr, Kbrown18. Peer reviewers: WucCP133, Dgarcia24, Maryam.havaei, Lizethrivera0720.

Above undated message substituted from Template:Dashboard.wikiedu.org assignment by PrimeBOT (talk) 06:21, 17 January 2022 (UTC)[reply]

Old talk

What's this? -- JeLuF 14:21 Dec 31, 2002 (UTC)

This stublet tells us absolutely nothing about the drug... what is it used for? etc... KJ

Seems to be solved by now. -- JeLuF 20:29 Jan 2, 2003 (UTC)

Words as Power - Expanding WikiProject Pharmacology

Kbrown18, Mlmtabs, NedaNassr, and Jcua28 will update the page accordingly:

  • Refine medical uses section to include a more comprehensive list of indications  Done
  • Provide a more detailed and updated mechanism of action  Done
  • Add a pharmacokinetics section to elaborate on absorption, distribution, metabolism, and elimination  Done
  • Add a special populations subsection under Medical uses for pregnancy, lactation, elderly, and newborn populations  Done
  • Refine side-effects section to include better references  Done
  • Update brand names and available forms section  Done
  • Add chemistry section  Done

Kbrown18 (talk) 18:49, 3 November 2016 (UTC)[reply]

  • Edited introduction to include other indications, common side-effects, pregnancy/lactation, renal and hepatic adjustment, history, trade names, and pricing. Jcua28 (talk) 18:23, 4 November 2016 (UTC)[reply]
  • Added pharmacokinetics section. Jcua28 (talk) 18:23, 4 November 2016 (UTC)[reply]
  • Edited brand names and dosage forms section. Jcua28 (talk) 18:23, 4 November 2016 (UTC)[reply]
  • Will add chemistry section to describe physical appearance, structure-activity relationships. Jcua28 (talk) 18:23, 4 November 2016 (UTC)[reply]
  • Added more information on the mechanism of action. Removed paragraph in Drug Interactions section regarding foscarnet and IV pentamidine increased risk of nephrotoxicity and hypocalcemia due to lack of citation. Kbrown18 (talk) 04:45, 5 November 2016 (UTC)[reply]
  • Added more to mechanism of action section from Foye's to include DNA binding, topoisomerase inhibition, and resistance mechanisms.
  • Re-added drug interactions of foscarnet into chemistry section due to IV incompatibility with added source. Jcua28 (talk) 22:50, 5 November 2016 (UTC)[reply]
  • Put medical uses into list format. Added preventative treatment of PCP for both children and adults with HIV with sources. Added sources to information that were missing citations. Removed paragraph about "treating Acanthamoeba infections" and "yeast infections caused by the organism Candida albicans" because no reputable sources that were also publicly available were found. I am thinking of removing "Acute PCP," "Primary and Secondary Prophylaxiss of PCP" because there are no sources and it is mentioned in the updated medical uses list. Let me know if anyone objects! Plan to keep use as a "anti-tumor drug" because there is a reputable source in the article. Mlmtabs (talk) 06:40, 7 November 2016 (UTC)[reply]
  • Removed "Acute PCP" and "Primary and Secondary Prophylaxis" sections in Medical Uses. No secondary sources to support information and already mentioned and cited in the medical uses list. Removed other indication about "special treatment schedules." Posting original text here (that was removed) in case anyone thinks it should stay in the article:
Acute PCP

In the acute treatment of PCP, pentamidine is considered equally or slightly less active than co-trimoxazole (brand names Bactrim, Septrin, or Septra). Clinical evidence suggests that pentamidine is often better tolerated than co-trimoxazole because a high dose of co-trimoxazole is needed, which is associated with a high incidence and severity of side effects such as hepatitis, bone-marrow-damage, renal-damage, and life-threatening skin disease (Lyell-syndrome). Moreover, many patients are or become allergic to co-trimoxazole. For treatment of PCP, 4 milligrams of pentamidine per kilogram of body weight is given intravenously once daily for 14 to 21 days. Treatment exceeding 21 days may be necessary, but is associated with increased toxicity. Intramuscular injection is not recommended. The effect of pentamidine often becomes evident within the first 2 days of treatment, with reduction in fever and improvement of respiratory function. In any case, improvements of chest radiograph (x-ray) studies occur within 6 to 8 days, provided therapy is successful. Pentamidine therapy cures 50 to 70% of all patients treated.

Primary and secondary prophylaxis of PCP Primary prophylaxis of severely immunocompromised patients can be indicated where PCP has not yet been diagnosed. Secondary prophylaxis aims to prevent recurrent infections by PCP. For both forms of prophylaxis, an aerosolized formulation of pentamidine given by nebulizer once monthly in a dose of 300 mg is used. In primary prophylaxis, this reduces the long term likelihood of PCP by 70% when compared to no prophylaxis. The aerosolized route of administration is well suited for pregnant women in their first trimester (when TMP-SMX is contraindicated). Aerosolized administration may lead to an atypical PCP infection involving the upper lobes.

Other

For other indications, such as leishmaniasis or sleeping sickness, special treatment schedules developed by the World Health Organization (WHO) or Centers for Disease Control (CDC) exist.

Mlmtabs (talk) 20:27, 7 November 2016 (UTC)[reply]

  • Updated "Contraindications" section by making it bullet-list format. Removed original text because lacked source and grammar errors. Added more detailed information with proper sources and citations. Previous text provided below:
  • "Severe allergy; no others in PCP patients in whom a proper diagnosis has been made."Mlmtabs (talk) 01:25, 9 November 2016 (UTC)[reply]
  • Added Special Populations section which includes pregnancy, breastfeeding, and elderly.NedaNassr (talk) 07:30, 9 November 2016 (UTC)[reply]
  • Changed the format of the side effects. Added a common and rare section with bullet points that went under each one and added a reference to each section.NedaNassr (talk) 08:14, 9 November 2016 (UTC)[reply]
  • Added a sources and citations to the special populations section.NedaNassr (talk) 08:19, 9 November 2016 (UTC)[reply]
  • Added a reference and cited each bullet point under "other" under the category of side effects. NedaNassr (talk) 21:11, 9 November 2016 (UTC)[reply]
  • Deleted the Note to add more references under the side effects. NedaNassr (talk) 21:20, 9 November 2016 (UTC)[reply]

CP133 Review

STUDENT 1 – Does the draft submission reflect a neutral point of view? If not, specify… Yes, the draft submission on Pentamidine reflects a neutral point of view. The article summarizes publicly available information and does not include clinical conclusions based on primary research or opinions by the editors.WucCP133 (talk) 21:28, 15 November 2016 (UTC)[reply]

STUDENT 2 – Are the points included verifiable with cited secondary sources that are freely accessible? If not, specify...No, not all sources are freely accessible, specifically Foye's Principles of Medicinal Chemistry (Seventh ed.), which is a book. A person would have to track down and purchase the book in order to cross reference the content used. Besides this, all other sources are freely accessible to the public. Albeit, there are multiple sources listed more than once in the references section. For example, the second source is listed again as the sixteenth source.

- Per the training module on wikiedu.org on Sources and Citations, use of "books or publications written by experts in the field, and published by reliable publishers" are permissible references. Jcua28 (talk) 00:22, 16 November 2016 (UTC)[reply]
- Revision: Removed duplicate source #16 and #15 and changed information previously cited with #16, #15 to #2 Mlmtabs (talk) 05:21, 17 November 2016 (UTC)[reply]
- Revision: Removed duplicate source #9 (WHO Drugs) because it was a duplicate for source #2 Mlmtabs (talk) 05:31, 17 November 2016 (UTC)[reply]
- Revision: Removed duplicate source #15 (DailyMed - NEBUPENT- pentamidine isethionate inhalant) and replaced with #8 Mlmtabs (talk) 05:34, 17 November 2016 (UTC)[reply]

STUDENT 3 – Are the edits formatted consistent with Wikipedia’s manual of style for medicine-related articles? If not, specify… Yes, the edits are overall consistent with Wikipedia’s manual of style for medicine-related articles. -Per Wikipedia Manual of Style/Linking, only the first occurrence of a term in the text of the article should be linked, therefore you may link trimethoprim-sulfamethoxazole in the Pregnancy section instead of the one in the Children section that comes later in the text. -Per Wikipedia in class workshop, use of pregnancy category should be avoided as different pregnancy category systems are used worldwide and the U.S pregnancy category may not be as clear to readers from other countries.Maryam.havaei (talk) 09:57, 16 November 2016 (UTC)[reply]

- Deleted "pregnancy category C" since it not a common universal term.NedaNassr (talk) 06:33, 17 November 2016 (UTC)[reply]

STUDENT 4 - Is there any evidence of plagiarism or copyright violation? If yes, specify... No, there is no evidence of plagiarism or copyright violations. Each added submission is followed by suitably cited sources. The editing that was submitted by each student was written in his/her own words and is supported by the sources included. When analyzed through a plagiarism checker, more than 96% of the text was found to be from http://en.wikipedia.org/wiki/Pentamidine without any other contributing sources. User:lizethrivera0720 (talk) 22:03, 15 November 2016 (UTC)[reply]

Retrieved from "https://mdwiki.org/wiki/Talk:Pentamidine"